Brokerages Set Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) PT at $17.25

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) has earned a consensus rating of “Hold” from the six analysts that are currently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $17.25.

Separately, Weiss Ratings lowered Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, May 15th.

Institutional Trading of Aurinia Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. BOK Financial Private Wealth Inc. purchased a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $32,000. Frazier Financial Advisors LLC increased its position in shares of Aurinia Pharmaceuticals by 411.9% during the first quarter. Frazier Financial Advisors LLC now owns 3,471 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 2,793 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Aurinia Pharmaceuticals during the third quarter worth about $48,000. Kemnay Advisory Services Inc. purchased a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $82,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Aurinia Pharmaceuticals by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,407 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 1,318 shares during the last quarter. 36.83% of the stock is owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Trading Down 0.1%

NASDAQ:AUPH opened at $15.33 on Tuesday. The business’s 50-day moving average is $15.49 and its two-hundred day moving average is $15.25. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.55 and a quick ratio of 5.01. Aurinia Pharmaceuticals has a 12 month low of $7.28 and a 12 month high of $16.88. The firm has a market capitalization of $1.97 billion, a PE ratio of 7.06 and a beta of 1.44.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.18 by $0.07. Aurinia Pharmaceuticals had a return on equity of 26.62% and a net margin of 99.97%.The company had revenue of $77.71 million for the quarter, compared to analyst estimates of $76.98 million. Research analysts predict that Aurinia Pharmaceuticals will post 0.82 earnings per share for the current fiscal year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.